Compare Atmos Energy Corporation (ATO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs TG Therapeutics Inc — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.59B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Atmos Energy Corporation is far larger — about 3.7× TG Therapeutics Inc's market cap, and Atmos Energy Corporation pays a 2.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ATO | TGTX | |
|---|---|---|
Market Cap | $28.59B | $7.64B |
Sector | Utilities | Health |
52-Week High | $192.25 | $59.06 |
52-Week Low | $162.44 | $26.94 |
Enterprise Value | $38.40B | $7.84B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.58, up 0.99% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q3 2026 earnings of $1.43 per share, beating estimates, and reaffirmed fiscal 2026 guidance. Revenue grew to $4.7 billion in 2025, with a net income margin of 28.5%, while the balance sheet shows $25.19 billion in total assets and manageable leverage.
The outlook is supported by consistent dividend payments and analyst consensus pointing to upside with a $190.57 price target. Key risks include high capital expenditure trends and interest rate sensitivity, but the utility's defensive profile and earnings momentum provide a stable investment case for income-focused shareholders.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
